Big Phar­ma has harsh words for UK's bal­loon­ing vol­un­tary re­im­burse­ment agree­ment

In the af­ter­math of Ab­b­Vie and Eli Lil­ly leav­ing the UK’s vol­un­tary drug pric­ing agree­ment in Jan­u­ary, some Big Phar­ma ex­ecs are still rais­ing ques­tions about an agree­ment that in­creas­ing­ly puts the cost of brand­ed med­i­cines on the com­pa­nies — as the agree­ment is set to ex­pire at the end of this year.

The is­sue re­volves around the coun­try’s “Vol­un­tary scheme for brand­ed med­i­cines pric­ing and ac­cess,” or VPAS — an agree­ment be­tween in­dus­try and the UK gov­ern­ment signed in 2019 in a bid to keep the prices of cer­tain med­ica­tions af­ford­able.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA